Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Nat Med. 2015 Feb 16;21(3):248–255. doi: 10.1038/nm.3806

Figure 2. MCC950 does not inhibit NLRC4, AIM2, TLR signalling or priming of NLRP3.

Figure 2

(a) Production of IL-1β and TNF-α from BMDM stimulated with LPS and S. typhimurium and treated with MCC950 and parthenolide measured by ELISA. Cytokine level is normalized to DMSO control treated cells. Data are expressed as mean ± S.E.M. of four independent experiments carried out in triplicate. (b) Western blots of cell lysates and supernatants from BMDM stimulated with LPS and S. typhimurium and treated with MCC950 and parthenolide. These results are representative of four independent experiments. (c) Production of IL-1β and TNF-α from BMDM stimulated with LPS and transfected Poly(dA:dT) and treated with MCC950 and Bayer compound measured by ELISA. Cytokine level is normalized to DMSO control treated cells. Data are expressed as mean ± S.E.M. of five independent experiments carried out in triplicate. (d) Western blots of cell lysates and supernatants from BMDM stimulated with LPS and transfected Poly(dA:dT) and treated with MCC950 and Bayer compound. These results are representative of two independent experiments. (e) Western blots of cell lysates from BMDM treated with MCC950 and stimulated with LPS (4 h). These results are representative of three independent experiments. (f) Production of TNF-α from BMDM treated with MCC950 and parthenolide and stimulated with LPS or Poly(A:U) measured by ELISA. Data shown represent mean cytokine level ± S.D. from triplicate determinations and are representative of three independent experiments.